Fraser P A, Stern S H, Coblyn J S, Weinblatt M E, Holdsworth D E, Green P, Shriner S, Mindnich D, Larson M
J Natl Med Assoc. 1988 Feb;80(2):162-5.
Typing for antigens HLA-A,B,C and DR was performed on 165 rheumatoid arthritis patients (14 black, 151 white) who had received gold therapy to determine the relationship between HLA antigens and gold dermatitis, stomatitis, thrombocytopenia, and proteinuria. Dermatitis and stomatitis occurred in both black and white patients. Thrombocytopenia and proteinuria occurred only among the white patients studied. The absence of thrombocytopenia and proteinuria among the black patients was not statistically significant. Antigen HLA-DR7 was uncommon among black and white subjects with dermatitis (0 of 6 blacks, 4 of 48 whites), but this decrease in frequency was not statistically significant. Antigen HLA-DR3 was an important risk factor for thrombocytopenia (relative risk = 11.8, P = .0043) and proteinuria (RR = 5.8, P = .032). These results are consistent with previous studies of HLA-DR3 and gold toxicity. The only black patient with stomatitis possessed the A1B8DR3 phenotype. Future studies should examine whether the same HLA antigen confers risk of different gold toxicities in different racial groups, and whether there are HLA antigens that provide a protective effect.
对165例接受金制剂治疗的类风湿性关节炎患者(14例黑人,151例白人)进行了HLA - A、B、C和DR抗原分型,以确定HLA抗原与金制剂所致皮炎、口腔炎、血小板减少症和蛋白尿之间的关系。黑人和白人患者均出现皮炎和口腔炎。血小板减少症和蛋白尿仅在研究的白人患者中出现。黑人患者未出现血小板减少症和蛋白尿,这一差异无统计学意义。抗原HLA - DR7在患皮炎的黑人和白人中均不常见(6例黑人中0例,48例白人中4例),但这种频率降低无统计学意义。抗原HLA - DR3是血小板减少症(相对风险=11.8,P = 0.0043)和蛋白尿(RR = 5.8,P = 0.032)的重要危险因素。这些结果与先前关于HLA - DR3和金制剂毒性的研究一致。唯一患口腔炎的黑人患者具有A1B8DR3表型。未来的研究应探讨同一HLA抗原在不同种族群体中是否会导致不同的金制剂毒性风险,以及是否存在具有保护作用的HLA抗原。